A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Part of paid clinical trials in Boulder, Colorado.
- Sponsor
- Alkermes, Inc.
- Study ID
- NCT07502443
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Narcolepsy Type 2
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- ALKS 2680 Dose 1 — DRUGParticipants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
- ALKS 2680 Dose 2 — DRUGParticipants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
- ALKS 2680 Dose 3 — DRUGParticipants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
- Placebo — DRUGParticipants will receive placebo tablets, daily, orally for 12 weeks
Study Details
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Key Dates
- Start date
- Apr 22, 2026
- Status verified
- Jun 2026
- Primary completion
- May 31, 2027
- Completion
- Jun 30, 2027
Study Design
- Enrollment
- 176 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ALKS 2680 Dose 1
- Experimental: ALKS 2680 Dose 2
- Experimental: ALKS 2680 Dose 3
- Placebo Comparator: Placebo
Primary Outcome Measure
Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level [ Time Frame: Baseline to Week 12 ]
Central Contacts
- Director Clinical Trial Manager888-235-8008 (US Only)
- Director Clinical Trial Manager571-599-2702 (Global)
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Alkermes Investigational Site | Boulder | Colorado | 80301 | - |
| Alkermes Investigational Site | Brandon | Florida | 33511 | - |
| Alkermes Investigational Site | Maimi | Florida | 33176 | - |
| Alkermes Investigational Site | Winter Park | Florida | 32789 | - |
| Alkermes Investigational Site | Macon | Georgia | 31210 | - |
| Alkermes Investigational Site | Newton | Massachusetts | 02459 | - |
| Alkermes Investigational Site | Lansing | Michigan | 48911 | - |
| Alkermes Investigational Site | Cincinnati | Ohio | 45245 | - |
| Alkermes Investigational Site | Wyomissing | Pennsylvania | 19610 | - |
| Alkermes Investigational Site | Columbia | South Carolina | 29201 | - |
| Alkermes Investigational Site | Austin | Texas | 78731 | - |
| Alkermes Investigational Site | San Antonio | Texas | 78229 | - |
| Alkermes Investigational Site | Sugar Land | Texas | 77478 | - |
Find similar trials in Boulder, CO
Related Studies
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPHASE2/PHASE3 · Recruiting · Alkermes, Inc. · Phoenix, Arizona
- A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)PHASE2 · Recruiting · Takeda · Auburn, Alabama
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama